Vir Biotechnology (VIR) said Thursday it has enrolled the first patient in a phase 3 study that will evaluate the efficacy and safety of its drug tobevibart in combination with elebsiran as a potential treatment for chronic hepatitis delta.
The trial is designed to provide the registrational data for submission to multiple regulatory agencies, the company said.
Chronic hepatitis delta is a severe inflammatory liver disease.
Shares were 0.5% higher in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。